ArticleGlobal medical genetics2025
Machine learning approach to identify significant genes and classify cancer types from RNA-seq data.
Article in Global medical genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer remains a leading cause of morbidity and mortality worldwide, with nearly 10 million deaths reported in 2022. In the United States, more than 618,000 deaths are projected to occur in 2025. Traditional methods for identifying cancer types are often time-consuming, labor-intensive, and resource-demanding, highlighting the need for efficient alternatives. This study aimed to evaluate machine learning algorithms on RNA-seq gene expression data to identify statistically significant genes and classify cancer types. We retrieved the PANCAN RNA-seq dataset from the UCI Machine Learning Repository and assessed eight classifiers-Support Vector Machines, K-Nearest Neighbors, AdaBoost, Random Forest, Decision Tree, Quadratic Discriminant Analysis, Naïve Bayes, and Artificial Neural Networks. Model performance was validated using a 70/30 train-test split and 5-fold cross-validation. Among the tested models, the Support Vector Machine achieved the highest classification accuracy of 99.87 % under 5-fold cross-validation. These findings demonstrate the potential of machine learning to efficiently analyze RNA-seq data, facilitate biomarker discovery, and support the development of personalized cancer diagnostics and treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.